» Articles » PMID: 32196098

Therapeutic Effect of Guggulsterone in Primary Cultured Orbital Fibroblasts Obtained From Patients with Graves' Orbitopathy

Overview
Specialty Ophthalmology
Date 2020 Mar 21
PMID 32196098
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Inflammation, hyaluronan production, and adipogenesis are the main pathological events leading to Graves' orbitopathy (GO). Guggulsterone (GS), a phytosterol found in the resin of the guggul plant, is a well-known treatment for several inflammatory disorders, such as arthritis, obesity, and hyperlipidemia. Here we investigated the effects of GS treatment on GO pathology.

Methods: Using primary cultures of orbital fibroblasts from GO patients and non-GO controls, we examined the effects of GS on hyaluronan production and the production of proinflammatory cytokines induced by interleukin (IL)-1β, using real-time reverse transcription-polymerase chain reaction analysis, western blots, and enzyme-linked immunosorbent assays. Further, adipogenic differentiation was evaluated by quantification of Oil Red O staining and assessment of protein levels of peroxisome proliferator activator gamma (PPARγ), CCAAT-enhancer-binding proteins (C/EBP) α and β, and sterol regulatory element-binding protein-1 (SREBP-1).

Results: Treatment with noncytotoxic concentrations of GS resulted in the dose-dependent inhibition of IL-1β-induced inflammatory cytokines, including IL-6, IL-8, MCP-1, and COX-2, at both mRNA and protein levels. The hyaluronan level was also significantly suppressed by GS. Moreover, GS significantly decreased the formation of lipid droplets and expression of PPARγ, C/EBP α/β, and SREBP-1 in a dose-dependent manner. GS pretreatment attenuated the phosphorylation of nuclear factor-kappa B induced by IL-1β.

Conclusions: Our data show significant inhibitory effects of GS on inflammation, production of hyaluronan, and adipogenesis in orbital fibroblasts. To our knowledge, this is the first in vitro preclinical evidence of the therapeutic effect of GS in GO.

Citing Articles

Prognostic significance of thyroid-stimulating hormone receptor antibodies in moderate-to-severe graves' orbitopathy.

Park J, Kim J, Kim S, Choi H Front Endocrinol (Lausanne). 2023; 14:1153312.

PMID: 37223049 PMC: 10200942. DOI: 10.3389/fendo.2023.1153312.


Guggulsterone Induces Apoptosis in Multiple Myeloma Cells by Targeting High Mobility Group Box 1 via Janus Activated Kinase/Signal Transducer and Activator of Transcription Pathway.

Akhtar S, Zarif L, Kuttikrishnan S, Prabhu K, Patil K, Nisar S Cancers (Basel). 2022; 14(22).

PMID: 36428714 PMC: 9688888. DOI: 10.3390/cancers14225621.


Guggulsterone Mediated JAK/STAT and PPAR-Gamma Modulation Prevents Neurobehavioral and Neurochemical Abnormalities in Propionic Acid-Induced Experimental Model of Autism.

Khera R, Mehan S, Bhalla S, Kumar S, Alshammari A, Alharbi M Molecules. 2022; 27(3).

PMID: 35164154 PMC: 8839522. DOI: 10.3390/molecules27030889.


Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases.

Li C, Yang J, Wang Y, Qi Y, Yang W, Li Y Front Pharmacol. 2020; 11:1247.

PMID: 32982723 PMC: 7479173. DOI: 10.3389/fphar.2020.01247.

References
1.
Kim B, Yoon J, Yang J, Myung S, Lee J, Jung E . Guggulsterone attenuates activation and survival of hepatic stellate cell by inhibiting nuclear factor kappa B activation and inducing apoptosis. J Gastroenterol Hepatol. 2013; 28(12):1859-68. DOI: 10.1111/jgh.12314. View

2.
Sabini E, Mazzi B, Profilo M, Mautone T, Casini G, Rocchi R . High Serum Cholesterol Is a Novel Risk Factor for Graves' Orbitopathy: Results of a Cross-Sectional Study. Thyroid. 2018; 28(3):386-394. DOI: 10.1089/thy.2017.0430. View

3.
Sinal C, Gonzalez F . Guggulsterone: an old approach to a new problem. Trends Endocrinol Metab. 2002; 13(7):275-6. DOI: 10.1016/s1043-2760(02)00640-9. View

4.
Yoon J, Lee H, Choi S, Chang E, Lee S, Lee E . Quercetin inhibits IL-1β-induced inflammation, hyaluronan production and adipogenesis in orbital fibroblasts from Graves' orbitopathy. PLoS One. 2011; 6(10):e26261. PMC: 3198474. DOI: 10.1371/journal.pone.0026261. View

5.
Mourits M, Koornneef L, Wiersinga W, Prummel M, Berghout A, van der Gaag R . Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br J Ophthalmol. 1989; 73(8):639-44. PMC: 1041835. DOI: 10.1136/bjo.73.8.639. View